Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Expression of matrix metalloproteinase-2 and 9 in cervical intraepithelial neoplasia and cervical carcinoma among different age groups of premenopausal and postmenopausal women.

Ghosh A, Moirangthem A, Dalui R, Ghosh T, Bandyopadhyay A, Dasgupta A, Banerjee U, Jana N, Basu A.

J Cancer Res Clin Oncol. 2014 Sep;140(9):1585-93. doi: 10.1007/s00432-014-1695-2. Epub 2014 May 8.

PMID:
24804816
2.

Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix.

Nasr M, Ayyad SB, El-Lamie IK, Mikhail MY.

Eur J Gynaecol Oncol. 2005;26(2):199-202.

PMID:
15857029
3.
4.

Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma.

Gaiotto MA, Focchi J, Ribalta JL, Stávale JN, Baracat EC, Lima GR, Guerreiro da Silva ID.

Am J Obstet Gynecol. 2004 May;190(5):1278-82.

PMID:
15167830
5.

MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.

Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G, Reich R.

Gynecol Oncol. 1999 Jun;73(3):372-82.

PMID:
10366463
6.

MMP-9/RECK Imbalance: A Mechanism Associated with High-Grade Cervical Lesions and Genital Infection by Human Papillomavirus and Chlamydia trachomatis.

Discacciati MG, Gimenes F, Pennacchi PC, Faião-Flores F, Zeferino LC, Derchain SM, Teixeira JC, Costa MC, Zonta M, Termini L, Boccardo E, Longatto-Filho A, Consolaro ME, Villa LL, Maria-Engler SS.

Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1539-47. doi: 10.1158/1055-9965.EPI-15-0420. Epub 2015 Aug 10.

7.

Early acquisition of gelatinolytic activity in carcinogenesis of the uterine cervix.

Minami R, Tsunoda H, Iijima T, Yoshikawa H, Nemori R, Noguchi M.

Mod Pathol. 2003 Nov;16(11):1164-70.

8.

Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.

Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Weis B, Ben-Baruch G, Reich R.

Gynecol Oncol. 1999 Mar;72(3):380-6.

PMID:
10053110
9.

MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation--an immunohistochemical study.

Brummer O, Böhmer G, Hollwitz B, Flemming P, Petry KU, Kühnle H.

Gynecol Oncol. 2002 Feb;84(2):222-7.

PMID:
11812078
10.
11.

Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia.

No JH, Jo H, Kim SH, Park IA, Kang D, Lee CH, Han SS, Kim JW, Park NH, Kang SB, Song YS.

Ann N Y Acad Sci. 2009 Aug;1171:100-4. doi: 10.1111/j.1749-6632.2009.04898.x. Erratum in: Ann N Y Acad Sci. 2009 Sep;1176:230.

PMID:
19723042
12.

Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.

Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Syrjänen S, Favalli C, Syrjänen K; HPV-PathogenISS Study Group.

Anticancer Res. 2006 Mar-Apr;26(2B):1543-56.

13.

Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion.

Zhai Y, Hotary KB, Nan B, Bosch FX, Muñoz N, Weiss SJ, Cho KR.

Cancer Res. 2005 Aug 1;65(15):6543-50.

14.

[The expression of matrix metalloproteinase-2 and -9 in cervical cancer and a study of their relationship].

Ouyang YW, Peng ZL, Yao XY, Liu SL, He YD.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 May;35(3):330-3. Chinese.

PMID:
15181827
15.

Genomic amplification of the human telomerase gene (TERC) in pap smears predicts the development of cervical cancer.

Heselmeyer-Haddad K, Sommerfeld K, White NM, Chaudhri N, Morrison LE, Palanisamy N, Wang ZY, Auer G, Steinberg W, Ried T.

Am J Pathol. 2005 Apr;166(4):1229-38.

16.

Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation.

Talvensaari A, Apaja-Sarkkinen M, Höyhtyä M, Westerlund A, Puistola U, Turpeenniemi T.

Gynecol Oncol. 1999 Mar;72(3):306-11.

PMID:
10053100
17.
18.

Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women.

Baltazar-Rodriguez LM, Anaya-Ventura A, Andrade-Soto M, Monrroy-Guizar EA, Bautista-Lam JR, Jonguitud-Olguin G, Cepeda-Lopez FR, Centeno-Aguilar VA, Gonzalez-Hernandez NA, Soriano-Hernández AD, Ramirez-Flores M, Lugo-Trampe A, Rodriguez-Sanchez IP, Newton-Sanchez OA, Delgado-Enciso I.

Biochem Genet. 2008 Apr;46(3-4):137-44. doi: 10.1007/s10528-007-9136-4. Epub 2008 Jan 22.

PMID:
18210196
19.

Differential DNA copy number aberrations in the progression of cervical lesions to invasive cervical carcinoma.

Oh EK, Kim YW, Kim IW, Liu HB, Lee KH, Chun HJ, Park DC, Oh EJ, Lee AW, Bae SM, Ahn WS.

Int J Oncol. 2012 Dec;41(6):2038-46. doi: 10.3892/ijo.2012.1644. Epub 2012 Sep 27.

PMID:
23023522

Supplemental Content

Support Center